What is Agenus?
Agenus researches, develops, and manufactures immuno-oncology products, including checkpoint antibodies, cell therapies, vaccines, and adjuvants. The company leverages its proprietary Retrocyte Display platform to generate fully human therapeutic antibody drug candidates. Headquartered in Lexington, Massachusetts, Agenus is dedicated to advancing the field of cancer immunotherapy through innovative scientific approaches and strategic capital infusion.
How much funding has Agenus raised?
Agenus has raised a total of $462.1M across 8 funding rounds:
Share Placement
$10M
Debt
$5M
Debt
$21.1M
Debt
$100M
Share Placement
$60M
Debt
$230M
Debt
$1M
Private Equity
$35M
Share Placement (2009): $10M with participation from Downsview Capital, Hudson Capital Group, and Iroquois Capital
Debt (2013): $5M, investors not publicly disclosed
Debt (2015): $21.1M, investors not publicly disclosed
Debt (2015): $100M, investors not publicly disclosed
Share Placement (2017): $60M backed by Incyte
Debt (2018): $230M with participation from HealthCare Royalty Partners
Debt (2020): $1M led by PPP
Private Equity (2020): $35M supported by Betta Pharmaceuticals Co., Ltd.
Key Investors in Agenus
Incyte
Incyte is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. While specific investment focus areas are not detailed here, their involvement suggests a strategic alignment with Agenus's immuno-oncology research.
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd. is a pharmaceutical company. Its participation in Agenus's funding round indicates a potential interest in the immuno-oncology space and the advancement of novel therapeutic candidates.
Hudson Capital Group
Hudson Capital Group is a private family office with a diversified investment portfolio including private equity and select start-up ventures. Their investment in Agenus suggests an interest in innovative biotechnology companies with high growth potential.
What's next for Agenus?
The recent major strategic investment in Agenus signals a critical phase for the company, likely aimed at scaling its operations and advancing its promising immuno-oncology pipeline through clinical trials. This enterprise-level funding suggests a strong investor confidence in Agenus's technology and its potential to deliver impactful cancer treatments. Future developments will likely focus on the progression of its antibody drug candidates and cell therapies, with the company poised for further growth and potential market expansion in the competitive biopharmaceutical landscape.
See full Agenus company page
